BridgeMD
New treatment option for Pancreatic Cancer, Adult
Official title Adebrelimab and Chidamide for Pancreatic Cancer
ClinicalTrials.gov ID: NCT06584227
What this study is testing
What is Adebrelimab and Chidamide Combined with Gemcitabine and S1?
Adebrelimab and Chidamide Combined with Gemcitabine and S1 is an investigational medicine, being studied as a potential treatment for pancreatic cancer, adult.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Pancreatic cancer is a kind of digestive system tumor with high malignant degree and poor prognosis. Most patients with pancreatic cancer are locally advanced or have distant metastases at the time of diagnosis, so it is extremely important to find effective drugs to control tumor metastasis.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- 18 to 75 years old;
- Histologically or cytologically confirmed pancreatic cancer (originating from the ductal epithelium of the pancreas) with clinically documented...
- have not previously received systematic antitumor therapy for the current stage of disease, including surgery (except stent placement), radiotherapy...
- There must be at least one measurable lesion as a target lesion (according to RECIST v1.1 standards);
- ECOG(American Eastern Cancer Collaboration) Physical status score: 0\~1;
You likely can't join if
- 1) Have received any of the following treatments:
- Previous treatment with ICIs or HDACi;
- Received the last anti-cancer treatment (including surgery, radiotherapy, etc.) within 4 weeks before enrollment;
- Received any other investigational drug/device treatment within 4 weeks prior to enrollment;
- Enrolling in another clinical study at the same time, unless it is an observational (non-treatment) clinical study or an treatment clinical study...
See the full eligibility criteria
- 18 to 75 years old;
- Histologically or cytologically confirmed pancreatic cancer (originating from the ductal epithelium of the pancreas) with clinically documented unresectable locally advanced or metastatic pancreatic cancer (stage III/IV...
- have not previously received systematic antitumor therapy for the current stage of disease, including surgery (except stent placement), radiotherapy, chemotherapy, targeting, immunotherapy or investigational therapy;
- There must be at least one measurable lesion as a target lesion (according to RECIST v1.1 standards);
- ECOG(American Eastern Cancer Collaboration) Physical status score: 0\~1;
- Expected survival ≥3 months;
- The function of major organs is good (no blood components, cell growth factors, whitening drugs, platelet drugs, anemia correction drugs are allowed within 14 days before enrollment);
- Women of childbearing age must have had a blood pregnancy test within 7 days prior to enrollment, with a negative result, and be willing to use an appropriate method of contraception during the trial period and for 6...
- Voluntarily participate in the study and sign the informed consent;
- Good compliance, agreed to cooperate with the survival follow-up.
- 1) Have received any of the following treatments:
- Previous treatment with ICIs or HDACi;
- Received the last anti-cancer treatment (including surgery, radiotherapy, etc.) within 4 weeks before enrollment;
- Received any other investigational drug/device treatment within 4 weeks prior to enrollment;
- Enrolling in another clinical study at the same time, unless it is an observational (non-treatment) clinical study or an treatment clinical study follow-up; 2) Patients known to be allergic to the components of the...
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, Jiangsu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.